300 related articles for article (PubMed ID: 16309366)
1. SELDI-TOF-MS proteomics of breast cancer.
Clarke CH; Buckley JA; Fung ET
Clin Chem Lab Med; 2005; 43(12):1314-20. PubMed ID: 16309366
[TBL] [Abstract][Full Text] [Related]
2. Clinical proteomics in breast cancer: a review.
Gast MC; Schellens JH; Beijnen JH
Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
[TBL] [Abstract][Full Text] [Related]
3. Fine-needle aspiration in PreservCyt: a novel and reproducible method for possible ancillary proteomic pattern expression of breast neoplasms by SELDI-TOF.
Fowler LJ; Lovell MO; Izbicka E
Mod Pathol; 2004 Aug; 17(8):1012-20. PubMed ID: 15195106
[TBL] [Abstract][Full Text] [Related]
4. [Proteomics and breast cancer].
Mathelin C; Tomasetto C; Cromer A; Rio MC
Gynecol Obstet Fertil; 2006 Dec; 34(12):1161-9. PubMed ID: 17123853
[TBL] [Abstract][Full Text] [Related]
5. SELDI-TOF serum proteomics and colorectal cancer: a current overview.
Gemoll T; Roblick UJ; Auer G; Jörnvall H; Habermann JK
Arch Physiol Biochem; 2010; 116(4-5):188-96. PubMed ID: 20615064
[TBL] [Abstract][Full Text] [Related]
6. [Detection and clinical significance of serum proteomic patterns of breast cancers by surface enhanced laser desorption/ionization time of flight mass spectrometry].
Zhang GQ; Du J; Pang D
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):204-7. PubMed ID: 16875606
[TBL] [Abstract][Full Text] [Related]
7. SELDI-TOF serum proteomics and breast cancer: which perspective?
Garrisi VM; Abbate I; Quaranta M; Mangia A; Tommasi S; Paradiso A
Expert Rev Proteomics; 2008 Dec; 5(6):779-85. PubMed ID: 19086858
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
[TBL] [Abstract][Full Text] [Related]
9. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.
Engwegen JY; Gast MC; Schellens JH; Beijnen JH
Trends Pharmacol Sci; 2006 May; 27(5):251-9. PubMed ID: 16600386
[TBL] [Abstract][Full Text] [Related]
10. [Proteic profiling SELDI-TOF and breast cancer: clinical potential applications].
Gonçalves A; Bertucci F; Birnbaum D; Borg JP
Med Sci (Paris); 2007 Mar; 23 Spec No 1():23-6. PubMed ID: 17669349
[TBL] [Abstract][Full Text] [Related]
11. [Use of laser capture microdissection and surface-enhanced laser desorption ionization time-of-flight mass spectrometry to screen differential proteins in lung adenocarcinoma and lung squamous carcinoma].
Tian YX; Yang SY; Nan YD; Zhang W; Zhou B; Bu LN; Huo SF; Yu JK; Zheng S
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(3):145-8. PubMed ID: 18361807
[TBL] [Abstract][Full Text] [Related]
12. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery.
Seibert V; Ebert MP; Buschmann T
Brief Funct Genomic Proteomic; 2005 May; 4(1):16-26. PubMed ID: 15975261
[TBL] [Abstract][Full Text] [Related]
13. [Surface enhanced laser desorption/ionization (SELDI): proteomics technology and its application in oncology].
Espejel F; Roa JC
Med Clin (Barc); 2008 Sep; 131(8):312-7. PubMed ID: 18803927
[TBL] [Abstract][Full Text] [Related]
14. Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS).
Gast MC; van Gils CH; Wessels LF; Harris N; Bonfrer JM; Rutgers EJ; Schellens JH; Beijnen JH
Clin Chem Lab Med; 2009; 47(6):694-705. PubMed ID: 19416081
[TBL] [Abstract][Full Text] [Related]
15. Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer.
Akashi T; Nishimura Y; Wakatabe R; Shiwa M; Yamori T
Biochem Biophys Res Commun; 2007 Jan; 352(2):514-21. PubMed ID: 17137555
[TBL] [Abstract][Full Text] [Related]
16. The value of surface enhanced laser desorption/ionization-time of flight mass spectrometry at the diagnosis of non-small cell lung cancer: a systematic review.
Jiang F; Zhou XY; Huang J
Technol Cancer Res Treat; 2014 Apr; 13(2):109-17. PubMed ID: 23862745
[TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis of archival breast cancer serum.
Zeidan BA; Cutress RI; Murray N; Coulton GR; Hastie C; Packham G; Townsend PA
Cancer Genomics Proteomics; 2009; 6(3):141-7. PubMed ID: 19487543
[TBL] [Abstract][Full Text] [Related]
18. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
Liu XP; Shen J; Li ZF; Yan L; Gu J
Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
[TBL] [Abstract][Full Text] [Related]
19. Study of distinct serum proteomics for the biomarkers discovery in colorectal cancer.
Xu W; Hu Y; Li J; He X; Fu Z; Pan T; Liu H; He H; Ge W; Yu J; Wei Q; Zheng S; Chen Y; Zhang S
Discov Med; 2015 Oct; 20(110):239-53. PubMed ID: 26562477
[TBL] [Abstract][Full Text] [Related]
20. [Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers].
Solassol J; Marin P; Maudelonde T; Mangé A
Bull Cancer; 2005 Sep; 92(9):763-8. PubMed ID: 16203265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
